Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Temsirolimus, After 1st Line Anti-VEGF Treatment in Patients With Advanced Renal Cancer.
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary)
- Indications Carcinoma; Renal cell carcinoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 11 Oct 2016 Results assessing safety and efficacy presented at the 41st European Society for Medical Oncology Congress.
- 01 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.